Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2021-08-03 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder for a picture and no substantive content or text. The true document length is only 54 characters, indicating it is extremely short and contains no report or announcement details. Given the lack of any financial data, regulatory references, or report content, this cannot be classified as a report or announcement. It falls under the fallback category for miscellaneous filings with no meaningful content.
2021-08-03 English
News Verification
Regulatory Filings Classification · 95% confidence The document text is very short (959 characters) and appears to be a response or clarification related to a stock exchange query, mentioning a court order and prior disclosures to the stock exchange. There is no indication of a full report, financial data, or detailed analysis. The content resembles a regulatory announcement or compliance communication rather than a full report or presentation. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length, it best fits the Regulatory Filings (RNS) category, which is a fallback for miscellaneous regulatory announcements and compliance documents.
2021-07-28 English
With reference to the above subject, we wish to inform you that we had given a press release as 'legal update' on 7th July, 2021 We further clarify that the news article 'timesofindia.indiatimes.c
Regulatory Filings
2021-07-28 English
Related Party Transaction for the FY 2020-21
Regulatory Filings
2021-07-12 English
Q4 Investor presentation for the FY 2020-21
Regulatory Filings
2021-07-12 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation for the Quarter ended March 2021" and is addressed to stock exchanges. It contains detailed business overview, financial performance highlights, product portfolio, and strategic information. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal financial report or regulatory filing. The length is substantial (15,000 characters), and it is not a brief announcement or certification. Therefore, the document fits the category of an Investor Presentation (IP).
2021-07-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.